A novel approach to the classification of epidermodysplasia verruciformis

International Journal of Dermatology

Volumn 57, Issue 11, 2018, Pages 1344-1350

  Huang, Simo ^a   Wu, Julie H ^a   Lewis, Daniel J ^a,b   Rady, Peter L ^b   Tyring, Stephen K ^b,c  

^a Baylor College of Medicine   (United States)

^b University of Texas Health Science Center at Houston   (United States)

^c CENTER FOR CLINICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CLASSIFICATION; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE; GENETIC HETEROGENEITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; NONHUMAN; REVIEW; WART VIRUS; CLASSIFICATION; COMPLICATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE;

ACTIN BINDING PROTEIN; CORONIN PROTEINS; ECM1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MACROPHAGE STIMULATING PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOH PROTEIN, HUMAN; SCATTER FACTOR; SCLEROPROTEIN; TMC6 PROTEIN, HUMAN; TMC8 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

EPIDERMODYSPLASIA VERRUCIFORMIS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEPATOCYTE GROWTH FACTOR; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; PROTO-ONCOGENE PROTEINS; RHO GTP-BINDING PROTEINS; TRANSCRIPTION FACTORS;

EID: 85053284156     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.14196     Document Type: Review

References (55)

1. Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32: 579–581
2. Lewandowsky F, Lutz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankung [in German]. Arch Dermatol Syphilol 1922; 141: 193–203
3. Lutzner MA, Blanchet-Bardon C, Orth G. Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 1984; 83(1 Suppl): 18s–25s
4. Yanagi T, Shibaki A, Tsuji-Abe Y, et al. Epidermodysplasia verruciformis and generalized verrucosis: the same disease? Clin Exp Dermatol 2006; 31: 390–393
5. Sri JC, Dubina MI, Kao GF, et al. Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol 2012; 66: 292–311
6. Crequer A, Troeger A, Patin E, et al. Human RHOH deficiency causes T-cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012; 122: 3239–3247
7. Crequer A, Picard C, Patin E, et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS ONE 2012; 7: e44010
8. Stray-Pedersen A, Jouanguy E, Crequer A, et al. Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy. J Clin Immunol 2014; 34: 871–890
9. O'Blenes C, Pasternak S, Issekutz A, et al. Epidermodysplasia verruciformis in lipoid proteinosis: case report and discussion of pathophysiology. Pediatr Dermatol 2015; 32: 118–121
10. Ferreira PG, Carvalho L, Gamboa F. A novel immunodeficiency syndrome as a rare cause of secondary pulmonary alveolar proteinosis: a diagnosis after 5 decades. Rev Port Pneumol 2014; 20: 273–278
11. Rogers HD, Macgregor JL, Nord KM, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009; 60: 315–320
12. Przybyszewska J, Zlotogorski A, Ramot Y. Reevaluation of epidermodysplasia verruciformis: reconciling more than 90 years of debate. J Am Acad Dermatol 2017; 76: 1161–1175. pii: S0190-9622(16)31296-8. https://doi.org/10.1016/j.jaad.2016.12.035
13. Slawsky LD, Gilson RT, Hockley AJ, et al. Epidermodysplasia verruciformis associated with severe immunodeficiency, lymphoma, and disseminated molluscum contagiosum. J Am Acad Dermatol 1992; 27: 448–450
14. Gross G, Ellinger K, Roussaki A, et al. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988; 91: 43–48
15. Kalińska-Bienias A, Kowalewski C, Majewski S. The EVER genes - the genetic etiology of carcinogenesis in epidermodysplasia verruciformis and a possible role in nonepidermodysplasia verruciformis patients. Postepy Dermatol Alergol 2016; 33: 75–80
16. Orth G. Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 2006; 18: 362–374
17. Ramoz N, Rueda LA, Bouadjar B, et al. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol 1999; 112: 259–263
18. Ramoz N, Taieb A, Rueda LA, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J Invest Dermatol 2000; 114: 1148–1153
19. Lutzner MA. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 1978; 65: 169–182
20. Lazarczyk M, Dalard C, Hayder M, et al. EVER proteins, key elements of the natural antihuman papillomavirus barrier, are regulated upon T-cell activation. PLoS ONE 2012; 7: e39995
21. Pereira de Oliveira WR, Carrasco S, Neto CF, et al. Nonspecific cell-mediated immunity in patients with epidermodysplasia verruciformis. J Dermatol 2003; 30: 203–209
22. Barzegar C, Paul C, Saiag P, et al. Epidermodysplasia verruciformis like eruption complicating human immunodeficiency virus infection. Br J Dermatol 1998; 139: 122–127
23. Patel AS, Karagas MR, Pawlita M, et al. Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case control study. Int J Cancer 2008; 122: 2377–2379
24. de Oliveira WR, Festa Neto C, Rady PL, et al. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2003; 17: 394–398
25. Orth G. Human papillomaviruses associated with epidermodysplasia verruciformis in nonmelanoma skin cancers: guilty or innocent? J Invest Dermatol 2005; 125: xii–xiii
26. Fox SH, Elston DM. Epidermodysplasia verruciformis and the risk for malignancy. Cutis 2016; 98: E10–E12
27. Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol 2009; 9: 630–644
28. Nehme NT, Pachlopnik Schmid J, Debeurme F, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012; 119: 3458–3468
29. Vu J, Wallace GR, Singh R, et al. Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol 2007; 8: 307–310
30. Gubinelli E, Posteraro P, Girolomoni G. Idiopathic CD4+ T lymphocytopenia associated with disseminated flat warts and alopecia areata. J Dermatol 2002; 29: 653–656
31. Stetson CL, Rapini RP, Tyring SK, et al. CD4+ T lymphocytopenia with disseminated HPV. J Cutan Pathol 2002; 29: 502–505
32. Manchado lopez P, Ruiz de Morales JM, Ruiz González I, et al. Cutaneous infections by papillomavirus, herpes zoster, and Candida albicans as the only manifestation of idiopathic CD4+ T lymphocytopenia. Int J Dermatol 1999; 38: 119–121
33. Lutzner M, Croissant O, Ducasse MF, et al. A potentially oncogenic human papillomavirus (HPV-5) found in two renal allograft recipients. J Invest Dermatol 1980; 75: 353–356
34. Lau C, Acharya S, Arumainayagam JT, et al. Acquired epidermodysplasia verruciformis in an HIV-positive patient. Int J STD AIDS 2016; 27: 1023–1025
35. Broekaert SM, Ehrchen J, Büttner R, et al. Acquired epidermodysplasia verruciformis in an HIV-infected patient. J Dtsch Dermatol Ges 2014; 12: 353–355
36. Castro-Perez GA, Sorin I, Bravo AI, et al. Acquired epidermodysplasia verruciformis in a patient with congenital HIV infection. Actas Dermosifiliogr 2013; 104: 731–733
37. Berk DR, Bruckner AL, Lu D. Epidermodysplasia verruciform-like Lesions in an HIV patient. Dermatol Online J 2009; 15: 1
38. Berger TG, Sawchuk WS, Leonardi C, et al. Epidermodysplasia verruciformis-associated papillomavirus infection complicating human immunodeficiency virus disease. Br J Dermatol 1991; 124: 79–83
39. Prose NS, von Knebel-Doeberitz C, Miller S, et al. Widespread flat warts associated with human papillomavirus type 5: a cutaneous manifestation of human immunodeficiency virus infection. J Am Acad Dermatol 1990; 23(5 Pt 2): 978–981
40. Jacobelli S, Laude H, Carlotti A, et al. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol 2011; 147: 590–596
41. Haas N, Fuchs PG, Hermes B, et al. Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient. Br J Dermatol 2001; 145: 669–670
42. Mermet I, Guerrini JS, Cairey-Remonnay S, et al. Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV-infected patient: a manifestation of immune restoration syndrome. Eur J Dermatol 2007; 17: 149–152
43. Vicente A, Pau-Charles I, González-Enseñat MA, et al. High-risk alpha-human papillomavirus types: detection in HIV-infected children with acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2013; 68: 343–345
44. Cowan KR, Gonzalez Santiago TM, Tollefson MM. Acquired epidermodysplasia verruciformis in a child with the human immunodeficiency virus. Pediatr Dermatol 2013; 30: e252–e254
45. Lowe SM, Katsidzira L, Meys R, et al. Acquired epidermodysplasia verruciformis due to multiple and unusual HPV infection among vertically infected, HIV-positive adolescents in Zimbabwe. Clin Infect Dis 2012; 54: e119–e123
46. Hirschman D, Tacastacas J, Rady PL, et al. Acquired Epidermodysplasia Verruciformis Associated with Human Papilloma Virus Type 14 in a Small Bowel Transplanted Child–A Case Report. Pediatr Dermatol 2016; 33: e1–e5
47. Cougoul P, Tournier E, Delavigne K, et al. Acquired epidermodysplasia verruciformis, a new opportunistic infection related to bendamustine. Ann Hematol 2015; 94: 1071–1073
48. Kirchhof MG, Au S. Brazilian waxing and human papillomavirus: a case of acquired epidermodysplasia verruciformis. CMAJ 2015; 187: 126–128. https://doi.org/10.1503/cmaj.140198
49. Fernandez KH, Rady P, Tyring S, et al. Acquired epidermodysplasia verruciformis in a child with atopic dermatitis. Pediatr Dermatol 2014; 31: 400–402
50. Mendes AD, Bittencourt Mde J, Moure ER, et al. Acquired epidermodysplasia verruciformis in a renal transplant recipient–case report. An Bras Dermatol 2014; 89: 144–146
51. Kunishige JH, Hymes SR, Madkan V, et al. Epidermodysplasia verruciformis in the setting of graft-versus-host disease. J Am Acad Dermatol 2007; 57(5 Suppl): S78–S80. PubMed PMID: 17938030
52. Zampetti A, Giurdanella F, Manco S, et al. Acquired epidermodysplasia verruciformis: a comprehensive review and a proposal for treatment. Dermatol Surg 2013; 39: 974–980
53. Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56: 882–886
54. Mcdermott DF, Gammon B, Snijders PJ, et al. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol 2009; 26: 306–310
55. Androphy EJ, Dvoretzky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred. Arch Dermatol 1985; 121: 864–868